文献速递淋巴瘤

纳武利尤单抗阻断PD-1治疗复发/难治性原发中枢神经系统淋巴瘤和睾丸淋巴瘤

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
PubMed 文献 · Blood · 2017-03-29

原发中枢神经系统淋巴瘤(PCNSL)和原发睾丸淋巴瘤(PTL)为罕见结外大B细胞淋巴瘤,缺乏标准治疗且预后差。研究在4例复发/难治PCNSL和1例PTL中枢复发患者中测试纳武利尤单抗,5例均获临床和影像学缓解,3例在13+至17+个月时仍无进展。

要点

  • 纳武利尤单抗在复发/难治PCNSL和PTL中显示活性。
  • 5例患者均获临床和影像学缓解,3例无进展生存13+至17+个月。
  • PCNSL和PTL频繁出现9p24.1拷贝数改变及PD-L1/PD-L2高表达。

核心结论

  • 数据提示纳武利尤单抗在复发/难治PCNSL和PTL中有活性,支持进一步研究PD-1阻断在这类疾病中的作用。

研究设计与样本

  • 在4例复发/难治PCNSL和1例PTL中枢复发患者中测试抗PD-1抗体纳武利尤单抗的疗效。

主要发现

  • 全部5例患者均对PD-1阻断有临床和影像学缓解。
  • 3例患者在13+至17+个月时仍无进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures. There are no standard-of-care treatment options for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor. PCNSLs and PTLs exhibit frequent 9p24.1 copy-number alterations and infrequent translocations of 9p24.1 and associated increased expression of the programmed cell death protein 1 (PD-1) ligands, PD-L1 and PD-L2. The activity of PD-1 blockade in other lymphomas with 9p24.1 alterations prompted us to test the efficacy of the anti-PD1 antibody, nivolumab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL. All 5 patients had clinical and radiographic responses to PD-1 blockade, and 3 patients remain progression-free at 13+ to 17+ months. Our data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017. PMID: 28356247. doi:10.1182/blood-2017-01-764209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。